Authors: Ashutosh N Shetty, Nasli R Ichaporia, Amod Tilak, Sonesh Kalra
Abstract
The non-Vitamin K oral anticoagulants (NOACs) help prevent stroke in patients of atrial fibrillation. However, management of patients on NOACs in emergency situations is a challenging prospect. Idarucizumab is approved globally as well as in India as the specific reversal agent for dabigatran. We report two cases with successful reversal using Idarucizumab in acute ischemic stroke and intracranial hemorrhage. Keywords: Atrial fibrillation, Bleeding, India, Stroke.
Open full article page